Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Chemicals

Kronos Worldwide Shares Plummet Following Disappointing Earnings Report

Robert Sasse by Robert Sasse
November 7, 2025
in Chemicals, Commodities, Earnings
0
Kronos Worldwide Stock
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Kronos Worldwide shares experienced a dramatic sell-off after the titanium dioxide producer released third-quarter results that fell significantly short of market expectations. The stock plummeted more than 11% in after-hours trading as investors reacted to unexpected losses and declining revenue figures.

Financial Performance Deteriorates

The company reported a net loss of $37 million, equivalent to $0.32 per share, for the third quarter of 2025. This represents a stark reversal from the $71.8 million profit recorded during the same period last year. On an adjusted basis, the loss stood at $0.18 per share, substantially worse than the $0.06 loss anticipated by market experts.

Revenue declined to $456.9 million, missing analyst projections of $477.3 million and marking a 6% decrease compared to the third quarter of 2024. The market response was immediate and severe.

Should investors sell immediately? Or is it worth buying Kronos Worldwide?

Market Challenges Weigh on Results

Several factors contributed to the company’s disappointing performance:

  • Average selling prices for titanium dioxide pigments dropped 7% year-over-year
  • Reduced production volumes resulted in approximately $27 million in unabsorbed fixed costs during the quarter
  • The TiO₂ segment reported a $15.3 million loss, compared to a $43.4 million profit in the prior year period
  • Operating income fell to negative $19.2 million
  • EBITDA margin collapsed from $123.3 million to just $0.6 million
  • Capacity utilization declined from 92% to 80%

Additional Pressures Emerge

Beyond challenging market conditions, Kronos Worldwide faced a non-cash tax charge of $19.3 million related to revised tax legislation in Germany. The company also cited ongoing market turbulence driven by geopolitical tensions, U.S. trade policies, and customer inventory management strategies as contributing factors.

The titanium dioxide market shows little indication of near-term recovery, leaving Kronos Worldwide fully exposed to the ongoing industry downturn. Current financial results and investor sentiment provide limited grounds for optimism about an immediate turnaround.

Ad

Kronos Worldwide Stock: Buy or Sell?! New Kronos Worldwide Analysis from February 7 delivers the answer:

The latest Kronos Worldwide figures speak for themselves: Urgent action needed for Kronos Worldwide investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Kronos Worldwide: Buy or sell? Read more here...

Tags: Kronos Worldwide
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Blue Ridge Bankshares Stock
Banking & Insurance

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

February 7, 2026
Next Post
SunCoke Energy Stock

SunCoke Energy Shares Plummet Despite Strong Quarterly Performance

Boeing Stock

Boeing's Survival Battle: Financial Distress Meets Glimmers of Hope

CommScope Stock

CommScope Shares Surge on Blockbuster Earnings and Strategic Transformation

Recommended

Torrid Holdings Stock

Torrid Holdings Faces Critical Earnings Test

5 months ago
Take-Two Stock

Take-Two Shares in Holding Pattern as Investors Await GTA VI Details

6 months ago
Union Pacific Stock

Union Pacific’s Future Hangs in Balance as Historic Railroad Merger Faces Critical Vote

4 months ago
Biotechnology Markets and money

BioTechnes Quarterly Earnings and Stock Performance Analysis

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Claros Mortgage Trust Secures Financial Flexibility Through Strategic Debt Overhaul

Trending

Vigil Neuroscience Stock
Healthcare

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

by SiterGedge
February 7, 2026
0

The integration of Vigil Neuroscience into French pharmaceutical giant Sanofi has been finalized. This strategic move, which...

Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Potbelly Stock

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success
  • Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com